|
1
|
Sainsbury R: The development of endocrine
therapy for women with breast cancer. Cancer Treat Rev. 39:507–517.
2013. View Article : Google Scholar
|
|
2
|
Mittendorf EA, Wu Y, Scaltriti M,
Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H,
Eksambi S, et al: Loss of HER2 amplification following
trastuzumab-based neoadjuvant systemic therapy and survival
outcomes. Clin Cancer Res. 15:7381–7388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scaltriti M, Eichhorn PJ, Cortés J,
Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A,
Ibrahim YH, et al: Cyclin E amplification/overexpression is a
mechanism of trastuzumab resistance in HER2+ breast
cancer patients. Proc Natl Acad Sci USA. 108:3761–3766. 2011.
View Article : Google Scholar
|
|
4
|
Burrows F, Zhang H and Kamal A: Hsp90
activation and cell cycle regulation. Cell Cycle. 3:1530–1536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zajac M, Gomez G, Benitez J and
Martínez-Delgado B: Molecular signature of response and potential
pathways related to resistance to the HSP90 inhibitor, 17AAG, in
breast cancer. BMC Med Genomics. 3:442010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Basso AD, Solit DB, Munster PN and Rosen
N: Ansamycin antibiotics inhibit Akt activation and cyclin D
expression in breast cancer cells that overexpress HER2. Oncogene.
21:1159–1166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song CH, Park SY, Eom KY, Kim JH, Kim SW,
Kim JS and Kim IA: Potential prognostic value of heat-shock protein
90 in the presence of phosphatidylinositol-3-kinase overexpression
or loss of PTEN, in invasive breast cancers. Breast Cancer Res.
12:R202010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Prodromou C and Pearl LH: Structure and
functional relationships of Hsp90. Curr Cancer Drug Targets.
3:301–323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Powers MV and Workman P: Targeting of
multiple signalling pathways by heat shock protein 90 molecular
chaperone inhibitors. Endocr Relat Cancer. 13(Suppl 1): S125–S135.
2006. View Article : Google Scholar
|
|
11
|
Hollingshead M, Alley M, Burger AM, Borgel
S, Pacula-Cox C, Fiebig HH and Sausville EA: In vivo antitumor
efficacy of 17-DMAG
(17-dimethylaminoethylamino-17-demethoxygeldanamycin
hydrochloride), a water-soluble geldanamycin derivative. Cancer
Chemother Pharmacol. 56:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith V, Sausville EA, Camalier RF, Fiebig
HH and Burger AM: Comparison of
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and
17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on
Hsp90 and client proteins in melanoma models. Cancer Chemother
Pharmacol. 56:126–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yerushalmi R, Gelmon KA, Leung S, Gao D,
Cheang M, Pollak M, Turashvili G, Gilks BC and Kennecke H:
Insulin-like growth factor receptor (IGF-1R) in breast cancer
subtypes. Breast Cancer Res Treat. 132:131–142. 2012. View Article : Google Scholar
|
|
15
|
Sieuwerts AM, Klijn JG, Peters HA and
Foekens JA: The MTT tetrazolium salt assay scrutinized: how to use
this assay reliably to measure metabolic activity of cell cultures
in vitro for the assessment of growth characteristics, IC50-values
and cell survival. Eur J Clin Chem Clin Biochem. 33:813–823.
1995.PubMed/NCBI
|
|
16
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar :
|
|
17
|
Miyata Y, Nakamoto H and Neckers L: The
therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des.
19:347–365. 2013. View Article : Google Scholar
|
|
18
|
Ochel HJ, Eichhorn K and Gademann G:
Geldanamycin: The prototype of a class of antitumor drugs targeting
the heat shock protein 90 family of molecular chaperones. Cell
Stress Chaperones. 6:105–112. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Modi S, Stopeck AT, Gordon MS, Mendelson
D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, et al:
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is
safe and active in trastuzumab-refractory HER-2 overexpressing
breast cancer: A phase I dose-escalation study. J Clin Oncol.
25:5410–5417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Modi S, Stopeck A, Linden H, Solit D,
Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME,
Sugarman S, et al: HSP90 inhibition is effective in breast cancer:
a phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Richardson PG, Chanan-Khan AA, Lonial S,
Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M
and Anderson KC: Tanespimycin and bortezomib combination treatment
in patients with relapsed or relapsed and refractory multiple
myeloma: Results of a phase 1/2 study. Br J Haematol. 153:729–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wagner AJ, Chugh R, Rosen LS, Morgan JA,
George S, Gordon M, Dunbar J, Normant E, Grayzel D and Demetri GD:
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride
(IPI-504) in patients with gastrointestinal stromal tumors or
soft-tissue sarcomas. Clin Cancer Res. 19:6020–6029. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ramanathan RK, Egorin MJ, Erlichman C,
Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP
and Belani CP: Phase I pharmacokinetic and pharmacodynamic study of
17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor
of heat-shock protein 90, in patients with advanced solid tumors. J
Clin Oncol. 28:1520–1526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jhaveri K, Miller K, Rosen L, Schneider B,
Chap L, Hannah A, Zhong Z, Ma W, Hudis C and Modi S: A phase I
dose-escalation trial of trastuzumab and alvespimycin hydrochloride
(KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin
Cancer Res. 18:5090–5098. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pacey S, Wilson RH, Walton M, Eatock MM,
Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U,
Roels B, et al: A phase I study of the heat shock protein 90
inhibitor alvespimycin (17-DMAG) given intravenously to patients
with advanced solid tumors. Clin Cancer Res. 17:1561–1570. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mosser DD, Caron AW, Bourget L,
Denis-Larose C and Massie B: Role of the human heat shock protein
hsp70 in protection against stress-induced apoptosis. Mol Cell
Biol. 17:5317–5327. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo
Y and Guo Y: Identification of metastasis-related proteins and
their clinical relevance to triple-negative human breast cancer.
Clin Cancer Res. 14:7050–7059. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daniel S, Bradley G, Longshaw VM, Söti C,
Csermely P and Blatch GL: Nuclear translocation of the
phosphoprotein Hop (Hsp70/Hsp90 organizing protein) occurs under
heat shock, and its proposed nuclear localization signal is
involved in Hsp90 binding. Biochim Biophys Acta. 1783:1003–1014.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hansen RK, Parra I, Lemieux P, Oesterreich
S, Hilsenbeck SG and Fuqua SA: Hsp27 overexpression inhibits
doxorubicin-induced apoptosis in human breast cancer cells. Breast
Cancer Res Treat. 56:187–196. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang SH, Kang KW, Kim KH, Kwon B, Kim SK,
Lee HY, Kong SY, Lee ES, Jang SG and Yoo BC: Upregulated HSP27 in
human breast cancer cells reduces Herceptin susceptibility by
increasing Her2 protein stability. BMC Cancer. 8:2862008.
View Article : Google Scholar : PubMed/NCBI
|
